An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

Inclusion Criteria: * Men with a history of prostate adenocarcinoma treated with local therapy (including radical prostatectomy or radical prostatectomy and secondary therapy \[i.e. salvage radiation\]) * Men must have biochemical recurrence (defined as PSA \>= 0.1ng/ml) after therapy * PSA \< 0.5ng/ml (within 90 days of enrollment) * Men must have had negative or equivocal PET PSMA based imaging with 90 days of enrollment with an Food and Drug Administration (FDA) approved non-POSLUMA tracer * Non-castrate testosterone (testosterone \[T\] \> 50ng/dL) within 90 days of study entry * Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on the study * Concurrent diseases and malignancies are permitted Exclusion Criteria: * Most recent PSA not between 0.1ng/ml and 0.5ng/ml * Men with non-metastatic castrate resistant prostate cancer (defined as rising PSA and T \< 50ng/dl) * Patients receiving 5-alpha reductase inhibitors, androgen deprivation therapy and androgen receptor antagonists within 3 months of enrollment (men may start these therapies at physician discretion immediately following POSLUMA PET PSMA scan)